Status:
COMPLETED
Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting
Lead Sponsor:
Centre Hospitalier de PAU
Conditions:
Bronchial Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This observational prospective monosite study aims to describe, for the first time, management in a hospital-at-home programme of patients treated by immunotherapy-chemotherapy combo for bronchial can...
Detailed Description
Those last years, immunotherapy treatment for bronchial cancers allowed considerable progress in terms of tumoral answer, survival without progression and global survival. Usually administered in the ...
Eligibility Criteria
Inclusion
- Patients aged 18 and over,
- with bronchial metastatic cancer treated in first row maintenance phase by immunotherapy-chemotherapy combo,
- having at least one assessments of the response to immunotherapy received in day hospitalization with efficiency (stability or partial response),
- without any graded higher than 1 adverse effects, or uncontrolled grade 1 adverse effects related to immunotherapy
- eligible for a home-based hospitalization
Exclusion
- Frail patients requiring a frequent medical assessment thus day hospitalization cares
Key Trial Info
Start Date :
September 29 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 8 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04802902
Start Date
September 29 2021
End Date
February 8 2024
Last Update
February 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de pau
Pau, Aquitaine, France, 64160